Journal of Infection and Chemotherapy

, Volume 17, Issue 6, pp 764–769 | Cite as

Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome

  • Tatsuyori ShozushimaEmail author
  • Gaku Takahashi
  • Naoya Matsumoto
  • Masahiro Kojika
  • Yoshikazu Okamura
  • Shigeatsu Endo
Original Article


CD14 is present in macrophage, monocyte, and granulocyte cells and their cell membranes, and it is said to be responsible for intracellular transduction of endotoxin signals. Its soluble fraction is present in blood and is thought to be produced in association with infections. It is called the soluble CD14-subtype (sCD14-ST), and in the following text it is referred to by its generic name, presepsin. We have previously reported that presepsin is produced in association with infection and that it is specifically expressed in sepsis. In the present study we developed a new rapid diagnostic method by using a chemiluminescent enzyme immunoassay that allowed making automated measurements in a shorter time. The results of using this method to measure presepsin values in different pathological conditions were normal, 294.2 ± 121.4 pg/ml; local infection, 721.0 ± 611.3 pg/ml; systemic inflammatory response syndrome, 333.5 ± 130.6 pg/ml; sepsis, 817.9 ± 572.7 pg/ml; and severe sepsis, 1,992.9 ± 1509.2 pg/ml; the presepsin values were significantly higher in patients with local infection, sepsis, and severe sepsis than in patients who did not have infection as a complication. In a comparative study with other diagnostic markers of sepsis based on ROC curves, the area under the curve (AUC) of presepsin was 0.845, and greater than the AUC of procalcitonin (PCT, 0.652), C-reactive protein (CRP, 0.815), or interleukin 6 (IL-6, 0.672). In addition, a significant correlation was found between the APACHE II scores, an index of disease severity, and the presepsin values, suggesting that presepsin values can serve as a parameter that closely reflects the pathology.


Sepsis SIRS Infection Soluble CD14-subtype Presepsin 



We express our sincere thanks to Mr. Kamon Shirakawa of the Mochida Pharmaceutical Co., Ltd., for his advice in carrying out this research. This study was funded in part by a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, and a grant from the Promotion and Mutual Aid Corporation for Private Schools of Japan.


  1. 1.
    Endo S, Sato N, Kasai T, Suzuki Y, Kojika M, Takahashi G, et al. Assessment of serum procalcitonin levels by immunochromatography: its significance as a rapid diagnostic technique for sepsis. Jpn J Crit Care Endotoxemia 2007;11:186–195 (in Japanese).Google Scholar
  2. 2.
    Endo S, Yaegashi Y, Sato N, Suzuki Y, Ogawa M, Kojika M, et al. Comparative study of soluble CD14 and soluble CD14-subtype in sepsis. Med Postgrad. 2006;44:381–5.Google Scholar
  3. 3.
    Endo S, Yaegashi Y, Sato N, Kojika M, Suzuki Y, Shirakawa K, et al. Usefulness of soluble CD14 subtype which as is a new diagnostic marker for sepsis. Jpn J Crit Care Endotoxemia 2005;9:46–950 (in Japanese).Google Scholar
  4. 4.
    Miyata M, Sato N, Takahashi G, Takahashi M, Endo S, Shirakawa K, et al. The utility of the soluble CD-14-subtype for diagnosis of sepsis, the examination of the simple diagnostic kit. J Iwate Med Assoc. 2007;59:325–31.Google Scholar
  5. 5.
    Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Endo S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11:234–8.PubMedCrossRefGoogle Scholar
  6. 6.
    ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for use of innovate therapies in sepsis. Crit Care Med 1992;20:867–874.Google Scholar
  7. 7.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.PubMedCrossRefGoogle Scholar
  8. 8.
    Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem 2008;375(1):144–146.Google Scholar

Copyright information

© Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2011

Authors and Affiliations

  • Tatsuyori Shozushima
    • 1
    Email author
  • Gaku Takahashi
    • 1
  • Naoya Matsumoto
    • 1
  • Masahiro Kojika
    • 1
  • Yoshikazu Okamura
    • 2
  • Shigeatsu Endo
    • 1
  1. 1.Department of Critical Care MedicineIwate Medical University, School of MedicineMoriokaJapan
  2. 2.Research and Development Division, R&D DepartmentMitsubishi Chemical Medience CorporationYachiyoJapan

Personalised recommendations